KR100409168B1 - 약제의결정변체 - Google Patents
약제의결정변체 Download PDFInfo
- Publication number
- KR100409168B1 KR100409168B1 KR10-1998-0708149A KR19980708149A KR100409168B1 KR 100409168 B1 KR100409168 B1 KR 100409168B1 KR 19980708149 A KR19980708149 A KR 19980708149A KR 100409168 B1 KR100409168 B1 KR 100409168B1
- Authority
- KR
- South Korea
- Prior art keywords
- variant
- weak
- medium
- difluorobenzyl
- triazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 22
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 12
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000005079 FT-Raman Methods 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000001237 Raman spectrum Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000002076 thermal analysis method Methods 0.000 description 3
- PVIAOIJYIQHKPL-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]triazole-4-carbonitrile Chemical compound FC1=CC=CC(F)=C1CN1N=NC(C#N)=C1 PVIAOIJYIQHKPL-UHFFFAOYSA-N 0.000 description 2
- OPJHWTKDQYKYHL-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1CC1=C(F)C=CC=C1F OPJHWTKDQYKYHL-UHFFFAOYSA-N 0.000 description 2
- JSZUBPHMRHROHZ-UHFFFAOYSA-N 2-(azidomethyl)-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1CN=[N+]=[N-] JSZUBPHMRHROHZ-UHFFFAOYSA-N 0.000 description 2
- OYUNTGBISCIYPW-UHFFFAOYSA-N 2-chloroprop-2-enenitrile Chemical compound ClC(=C)C#N OYUNTGBISCIYPW-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004279 X-ray Guinier Methods 0.000 description 1
- 238000005147 X-ray Weissenberg Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- XVEURJOWGBWEPY-UHFFFAOYSA-N methyl 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxylate Chemical compound N1=NC(C(=O)OC)=CN1CC1=C(F)C=CC=C1F XVEURJOWGBWEPY-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH140497 | 1997-06-10 | ||
| CH1404/97 | 1997-06-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR19990087835A KR19990087835A (ko) | 1999-12-27 |
| KR100409168B1 true KR100409168B1 (ko) | 2004-01-31 |
Family
ID=4209650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-1998-0708149A Expired - Lifetime KR100409168B1 (ko) | 1997-06-10 | 1998-06-08 | 약제의결정변체 |
| KR10-1998-0708150A Expired - Lifetime KR100425656B1 (ko) | 1997-06-10 | 1998-06-08 | 약제의결정변체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-1998-0708150A Expired - Lifetime KR100425656B1 (ko) | 1997-06-10 | 1998-06-08 | 약제의결정변체 |
Country Status (36)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| AR040233A1 (es) * | 2002-05-31 | 2005-03-23 | Schering Corp | Polimorfos inhibidores de xantina fosfodiesterasa v |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
| US20090069390A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched rufinamide |
| CA2736703A1 (en) | 2008-10-13 | 2010-04-22 | Cipla Limited | Process for the preparation of rufinamide |
| CN101768124B (zh) * | 2008-12-30 | 2012-01-04 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
| IT1395736B1 (it) * | 2009-08-04 | 2012-10-19 | Dipharma Francis Srl | Forme cristalline di rufinamide |
| EP2963023B1 (en) * | 2009-09-04 | 2018-04-18 | Tactical Therapeutics, Inc. | Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives |
| EP2465853A1 (en) * | 2010-12-14 | 2012-06-20 | Laboratorios Lesvi, S.L. | Polymorph of rufinamide and process for obtaining it |
| EP2727914A1 (en) | 2010-04-30 | 2014-05-07 | Laboratorios Lesvi, S.L. | Polymorph of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-carboxamide |
| ITMI20110718A1 (it) | 2011-04-29 | 2012-10-30 | Dipharma Francis Srl | Procedimento per la purificazione di rufinamide |
| US10206874B2 (en) | 2012-07-20 | 2019-02-19 | Hetero Research Foundation | Rufinamide solid dispersion |
| WO2021099481A1 (en) | 2019-11-20 | 2021-05-27 | Medichem, S.A. | Solid composition containing rufinamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992378A (en) | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
| US4156734A (en) | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
| GB1511195A (en) | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4346097A (en) * | 1980-09-30 | 1982-08-24 | Warner-Lambert Company | Method for treating convulsions with pyrazole-4-carboxamide derivatives |
| FI834666A7 (fi) | 1982-12-23 | 1984-06-24 | Ciba Geigy Ag | Foerfarande foer framstaellning av nya aralkyltriazolfoereningar. |
| US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
| US4511572A (en) * | 1983-03-18 | 1985-04-16 | The University Of Kentucky Research Foundation | Triazoline anticonvulsant drugs |
| PH22568A (en) * | 1985-04-18 | 1988-10-17 | Ciba Geigy Ag | Fluorinated benzyl triazoles and pharmaceutical compositions containing the same |
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| JPH02214504A (ja) | 1989-02-15 | 1990-08-27 | Nissan Chem Ind Ltd | 光学活性キノキサリン化合物の晶析法 |
| EP0484437A4 (en) | 1989-07-27 | 1994-06-01 | Searle & Co | Renal-selective prodrugs for the treatment of hypertension |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| HU221425B (en) | 1990-11-06 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds |
| JP2753911B2 (ja) | 1991-12-06 | 1998-05-20 | キッセイ薬品工業株式会社 | Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法 |
| DE4217952A1 (de) | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| GB9419318D0 (en) | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
| CN1072215C (zh) | 1995-02-22 | 2001-10-03 | 赫彻斯特药品和化学品公司 | 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途 |
| WO1998002423A1 (en) * | 1996-07-11 | 1998-01-22 | Novartis Ag | Process for preparing 1-substituted 4-cyano-1,2,3-triazoles |
| TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
-
1998
- 1998-06-04 TW TW087108859A patent/TW403740B/zh not_active IP Right Cessation
- 1998-06-04 TW TW087108858A patent/TW526195B/zh not_active IP Right Cessation
- 1998-06-08 KR KR10-1998-0708149A patent/KR100409168B1/ko not_active Expired - Lifetime
- 1998-06-08 AT AT98934930T patent/ATE237599T1/de active
- 1998-06-08 RU RU99104300/04A patent/RU2198167C2/ru active
- 1998-06-08 ES ES98934930T patent/ES2197485T3/es not_active Expired - Lifetime
- 1998-06-08 RU RU99104299/04A patent/RU2194041C2/ru active
- 1998-06-08 ID IDW980066D patent/ID21014A/id unknown
- 1998-06-08 NZ NZ331371A patent/NZ331371A/xx not_active IP Right Cessation
- 1998-06-08 NZ NZ331370A patent/NZ331370A/xx not_active IP Right Cessation
- 1998-06-08 CN CN988000113A patent/CN1132820C/zh not_active Expired - Lifetime
- 1998-06-08 IL IL12573398A patent/IL125733A/en active Protection Beyond IP Right Term
- 1998-06-08 HU HU0002113A patent/HU225153B1/hu unknown
- 1998-06-08 AU AU84372/98A patent/AU725517B2/en not_active Expired
- 1998-06-08 WO PCT/EP1998/003428 patent/WO1998056773A1/en not_active Ceased
- 1998-06-08 CA CA2614926A patent/CA2614926C/en not_active Expired - Lifetime
- 1998-06-08 AU AU84371/98A patent/AU725528B2/en not_active Expired
- 1998-06-08 JP JP53628998A patent/JP3672575B2/ja not_active Expired - Lifetime
- 1998-06-08 DK DK98934930T patent/DK0994864T3/da active
- 1998-06-08 CN CNB988056755A patent/CN1159300C/zh not_active Expired - Lifetime
- 1998-06-08 SI SI9830450T patent/SI0994864T1/xx unknown
- 1998-06-08 CZ CZ19982534A patent/CZ292260B6/cs not_active IP Right Cessation
- 1998-06-08 PL PL330798A patent/PL192114B1/pl unknown
- 1998-06-08 EP EP98934930A patent/EP0994864B1/en not_active Expired - Lifetime
- 1998-06-08 DK DK98934929T patent/DK0994863T3/da active
- 1998-06-08 SI SI9830405T patent/SI0994863T1/xx unknown
- 1998-06-08 JP JP53628898A patent/JP3672574B2/ja not_active Expired - Lifetime
- 1998-06-08 TR TR1998/01630T patent/TR199801630T1/xx unknown
- 1998-06-08 US US09/125,329 patent/US6740669B1/en not_active Expired - Lifetime
- 1998-06-08 CA CA002256013A patent/CA2256013C/en not_active Expired - Lifetime
- 1998-06-08 SK SK1094-98A patent/SK283734B6/sk not_active IP Right Cessation
- 1998-06-08 CN CNB2004100473675A patent/CN1298708C/zh not_active Expired - Lifetime
- 1998-06-08 DE DE69813560T patent/DE69813560T2/de not_active Expired - Lifetime
- 1998-06-08 EP EP98934929A patent/EP0994863B1/en not_active Expired - Lifetime
- 1998-06-08 BR BR9804946A patent/BR9804946A/pt not_active Application Discontinuation
- 1998-06-08 PT PT98934930T patent/PT994864E/pt unknown
- 1998-06-08 HU HU0000798A patent/HU226107B1/hu unknown
- 1998-06-08 ES ES98934929T patent/ES2192779T3/es not_active Expired - Lifetime
- 1998-06-08 PE PE1998000479A patent/PE80999A1/es not_active IP Right Cessation
- 1998-06-08 AT AT98934929T patent/ATE232852T1/de active
- 1998-06-08 KR KR10-1998-0708150A patent/KR100425656B1/ko not_active Expired - Lifetime
- 1998-06-08 IL IL12573298A patent/IL125732A/en not_active IP Right Cessation
- 1998-06-08 DE DE69811500T patent/DE69811500T2/de not_active Expired - Lifetime
- 1998-06-08 DE DE122007000051C patent/DE122007000051I2/de active Active
- 1998-06-08 WO PCT/EP1998/003427 patent/WO1998056772A1/en not_active Ceased
- 1998-06-08 PL PL330764A patent/PL191943B1/pl unknown
- 1998-06-08 ID IDW980065D patent/ID27660A/id unknown
- 1998-06-08 CA CA002256015A patent/CA2256015C/en not_active Expired - Lifetime
- 1998-06-08 CZ CZ19982533A patent/CZ292481B6/cs not_active IP Right Cessation
- 1998-06-08 PE PE1998000478A patent/PE79799A1/es not_active IP Right Cessation
- 1998-06-08 BR BR9804947A patent/BR9804947A/pt not_active Application Discontinuation
- 1998-06-08 SK SK1093-98A patent/SK283685B6/sk not_active IP Right Cessation
- 1998-06-08 TR TR1998/01631T patent/TR199801631T1/xx unknown
- 1998-06-09 AR ARP980102708A patent/AR012946A1/es not_active Application Discontinuation
- 1998-06-09 MY MYPI98002570A patent/MY120156A/en unknown
- 1998-06-09 MY MYPI98002572A patent/MY125854A/en unknown
- 1998-06-09 ZA ZA984967A patent/ZA984967B/xx unknown
- 1998-06-09 ZA ZA984966A patent/ZA984966B/xx unknown
- 1998-06-09 CO CO98032879A patent/CO4940452A1/es unknown
- 1998-06-09 CO CO98032885A patent/CO4940448A1/es unknown
- 1998-06-09 AR ARP980102707A patent/AR012945A1/es not_active Application Discontinuation
- 1998-08-11 NO NO19983667A patent/NO329315B1/no not_active IP Right Cessation
- 1998-08-11 NO NO19983666A patent/NO329314B1/no not_active IP Right Cessation
-
1999
- 1999-12-10 UY UY25844A patent/UY25844A1/es not_active Application Discontinuation
-
2001
- 2001-05-31 US US09/871,366 patent/US6455556B2/en not_active Expired - Lifetime
-
2002
- 2002-11-14 US US10/294,408 patent/US20030125568A1/en not_active Abandoned
-
2004
- 2004-02-26 US US10/787,528 patent/US20040167186A1/en not_active Abandoned
-
2006
- 2006-01-11 US US11/329,945 patent/US7750028B2/en not_active Expired - Fee Related
-
2007
- 2007-05-17 AR ARP070102132A patent/AR061005A2/es not_active Application Discontinuation
- 2007-05-17 AR ARP070102131A patent/AR061004A2/es unknown
- 2007-07-03 NL NL300284C patent/NL300284I2/nl unknown
- 2007-07-04 LU LU91345C patent/LU91345I2/fr unknown
- 2007-07-06 FR FR07C0037C patent/FR07C0037I2/fr active Active
- 2007-07-13 CY CY200700014C patent/CY2007014I2/el unknown
-
2010
- 2010-04-26 US US12/767,003 patent/US8076362B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8076362B2 (en) | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof | |
| US20020016351A1 (en) | New crystals of celecoxib | |
| SU873884A3 (ru) | Способ получени производных имидазолилэтоксипиразоло/3,4-в/пиридин-5-метанолов или их солей | |
| HK1028241B (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic | |
| MXPA98006951A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic | |
| MXPA98006950A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic | |
| HK1028242B (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19981012 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20001223 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20021202 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20030428 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20021202 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20030728 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20030428 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20030905 Appeal identifier: 2003101002963 Request date: 20030728 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20030728 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20030728 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20030203 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20001223 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20030905 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20030830 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20031128 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20031201 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20061124 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20071123 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20081126 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20091123 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20101125 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20111101 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20121031 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121031 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20131101 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131101 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141107 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20151030 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151030 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161028 Start annual number: 14 End annual number: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20171027 Year of fee payment: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20171027 Start annual number: 15 End annual number: 15 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20181208 Termination category: Expiration of duration |